Glaxosmithkline Share News (GSK)

Brexit is the wrong prescription, says European pharma industry

* Threat to regulatory system and research collaboration * UK exit seen harming British and European pharma sector By Ben Hirschler LONDON, Feb 24 (Reuters) - Britain's departure from the European Union would threaten scientific research and jeopardise the 28-nation bloc's syste

Business Leaders Warn Brexit Would "Deter Investment, Threaten Jobs"

Merck KGaA says consumer health saw 'nice' growth in 2015

By Ludwig Burger and Patricia Weiss DARMSTADT, Germany, Feb 23 (Reuters) - German drugs and chemicals group Merck KGaA has seen solid growth at its consumer healthcare business last year, underpinning the family-owned company's commitment to holding on to the business. The division, a

Monday broker round-up

(ShareCast News) - Coca-Cola Hbc: JP Morgan reiterates neutral with a target price of 1450p, Nomura stays at buy with a 1330p target and Deutsche Bank keeps at hold with a target price of 1500p. Standard Life: JP Morgan keeps at overweight with a target of 465p and Deutsche Bank reiterates buy, 415p

BROKER RATINGS SUMMARY: JPMorgan Upgrades Essentra To Overweight

Sunday newspaper round-up: GSK, Sainsbury's, BT, Imagination Technologies

(ShareCast News) - Financial institutions in the City of London are fairly pleased with David Cameron's agreement with the European Union ahead of June's referendum as it looks to have secured the Square Mile from excessive further Brussels red tape. A potentially painful sticking point has been avo

BROKER RATINGS SUMMARY: Macquarie Starts Burberry At Outperform

LONDON BRIEFING: Coca-Cola HBC And Standard Life Impress With Results

LONDON MARKET CLOSE: Commodity, Ex-Dividend Stocks Weigh On FTSE 100

LONDON MARKET MIDDAY: NY Called Higher As Ex-Dividends Damp FTSE 100

WINNERS & LOSERS SUMMARY: Investors Warm To Centrica Results

LONDON MARKET OPEN: Ex-Dividends Weigh On FTSE 100 As Centrica Rises

Friday broker round-up

(ShareCast News) - Cambian Group: Berenberg downgrades to hold with a target of 60p. Shaftesbury: Credit Suisse upgrades to outperform with a target price of 945p. Acacia Mining: UBS and Deutsche Bank reiterate buy with a target of 275p and 280p respectively. Ashmore: Citigroup stays at buy with a

TOP NEWS SUMMARY: UK Regulator Fines GlaxoSmithKline GBP38 Million

UPDATE 2-UK watchdog fines GSK $54 mln over 'pay-for-delay' drug deals

* CMA says GSK delayed generic competition to Seroxat * GSK disagrees and considering grounds for appeal * Merck KGaA also fined as former parent of generic firm (Adds Merck comment) By Ben Hirschler LONDON, Feb 12 (Reuters) - Britain's competition watchdog has fined Gla